Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells

Journal of Cellular Biochemistry

Volumn 112, Issue 6, 2011, Pages 1696-1707

  Ruvolo, Peter P ^a,b   Zhou, Liran ^a   Watt, Julie C ^a   Ruvolo, Vivian R ^a,b   Burks, Jared K ^a   Jiffar, Tilahun ^a,b   Kornblau, Steven ^a   Konopleva, Marina ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Minnesota Hormel Institute   (United States)

Author keywords

ACUTE MYELOID LEUKEMIA; BCL2; ENZASTAURIN; PROTEIN KINASE C

Indexed keywords

ENZASTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE C;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANTIGENS, CD34; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HL-60 CELLS; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 79954456301     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23090     Document Type: Article

References (52)

1. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA,. 1999. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. Leukemia 13: 1109-1166. (Pubitemid 29396575)
2. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y,. 1982. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257: 7847-7851. (Pubitemid 12043279)
3. Castro-Galache MD, Menéndez-Gutiérrez MP, Carrasco Garcia E, Garcia-Morales P, Martinez-Lacaci I, Saceda M, Ferragut JA,. 2007. Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. Int J Biochem Cell Biol 39: 1877-1885. (Pubitemid 47321348)
4. Corbalán-García S, Gõmez-Fernández JC,. 2006. Protein kinase C regulatory domains: The art of decoding many different signals in membranes. Biochim Biophys Acta 1761: 633-654. (Pubitemid 44177524)
5. Deng X, Ito T, Carr B, Mumby M, May WS,. 1998. Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 273: 34157-34163. (Pubitemid 29008888)
6. Deng X, Ruvolo P, Carr B, May WS,. 2000. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 97: 1578-1583. (Pubitemid 30118484)
7. Deng X, Kornblau SM, Ruvolo PP, May WS,. 2001. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 28: 30-37.
8. Detjen KM, Brembeck FH, Welzel M, Kaiser A, Haller H, Wiedenmann B, Rosewicz S,. 2000. Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci 113: 3025-3035.
9. Farrar WL, Thomas TP, Anderson WB,. 1985. Altered cytosol/membrane enzyme redistribution on interleukin-3 activation of protein kinase C. Nature 315: 235-237. (Pubitemid 15064451)
10. Gallegos LL, Newton AC,. 2008. Spatiotemporal dynamics of lipid signaling: Protein kinase C as a paradigm. IUBMB Life 60: 782-789.
11. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D,. 2005. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462-7469. (Pubitemid 41161281)
12. Grandage VL, Everington T, Linch DC, Khwaja A,. 2006. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 135: 303-316. (Pubitemid 44484837)
13. Griner EM, Kazanietz MG,. 2007. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7: 281-294. (Pubitemid 46480971)
14. Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T, Kuenen B, Thornton D, McNealy P, Giaccone G,. 2009. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 20: 1565-1575.
15. Herbst RS, Oh Y, Wagle A, Lahn M,. 2007. Enzastaurin, a protein kinase C beta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res 13: s4641-s4646.
16. Jiffar T, Kurinna S, Suck G, Carlson-Bremer D, Ricciardi MR, Konopleva M, Andreeff M, Ruvolo PP,. 2004. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 18: 505-512. (Pubitemid 38425865)
17. Kitatani K, Idkowiak-Baldys J, Hannun YA,. 2007. Mechanism of inhibition of sequestration of protein kinase C alpha/betaII by ceramide. Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/betaII on threonine 638/641. J Biol Chem 282: 20647-20656. (Pubitemid 47100048)
18. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M,. 2002. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99: 326-335.
19. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M,. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388. (Pubitemid 44693472)
20. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M,. 2006. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108: 2358-2365. (Pubitemid 44497520)
21. Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA,. 2009. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 15: 3617-3623.
22. Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP,. 2006. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia 20: 1316-1319. (Pubitemid 43905845)
23. Letai AG,. 2008. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8: 121-132. (Pubitemid 351161322)
24. Li W, Zhang J, Flechner L, Hyun T, Yam A, Franke TF, Pierce JH,. 1999. Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal. Oncogene 18: 6564-6572.
25. Ma S, Rosen ST,. 2007. Enzastaurin. Curr Opin Oncol 19: 590-595. (Pubitemid 47508866)
26. Mackay HJ, Twelves CJ,. 2007. Targeting the protein kinase C family: Are we there yet ? Nat Rev Cancer 7: 554-562. (Pubitemid 46985395)
27. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE,. 1994. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 269: 26865-26870. (Pubitemid 24332884)
28. Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH,. 2010. Protein kinase C beta modulates ligand-induced cell surface death receptor accumulation: A mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem 285: 888-902.
29. Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M,. 2008. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 19: 247-253. (Pubitemid 351209293)
30. Müller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K,. 1995. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14: 1961-1969.
31. Murray NR, Davidson LA, Chapkin RS, Gustafson W, Schattenberg DG, Fields AP,. 1999. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J. Cell Biol 145: 699-711. (Pubitemid 29240849)
32. Newton AC,. 2010. Protein kinase C: Poised to signal. Am J Physiol Endocrinol Metab 298: E395-E402.
33. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G,. 2008. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26: 1135-1141.
34. Perrotti D, Iervolino A, Cesi V, Cirinná M, Lombardini S, Grassilli E, Bonatti S, Claudio PP, Calabretta B,. 2000. BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase C betaII-dependent pathway. Mol Cell Biol 20: 6159-6169. (Pubitemid 30613063)
35. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C,. 2001. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19: 1485-1492. (Pubitemid 32202557)
36. Redig AJ, Platanias LC,. 2007. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J Interferon Cytokine Res 27: 623-636.
37. Redig AJ, Platanias LC,. 2008. Protein kinase C signalling in leukemia. Leuk Lymphoma 49: 1255-1262. (Pubitemid 352015788)
38. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA,. 2007. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-1746. (Pubitemid 46797955)
39. Ruvolo PP, Deng X, Carr BK, May WS,. 1998. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273: 25436-25442. (Pubitemid 28443312)
40. Ruvolo PP, Deng X, Ito T, Carr BK, May WS,. 1999. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 274: 20296-20300.
41. Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA, Ruvolo PP,. 2008. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem 283: 35474-35485.
42. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W,. 2006. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107: 2517-2524. (Pubitemid 43345576)
43. Sauma SZ, Yan ZS, Ohno S, Friedman E,. 1996. Protein kinase C beta 1 and protein kinase C beta 2 activate p57 mitogenactivated protein kinase and block differentiation in colon carcinoma cells. Cell Growth Differ 7: 587-594. (Pubitemid 26360757)
44. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM,. 2001. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19: 2319-2333. (Pubitemid 32366984)
45. Silverstein AM, Barrow CA, Davis AJ, Mumby MC,. 2002. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci USA 99: 4221-4226. (Pubitemid 34285967)
46. Strack S, Cribbs JT, Gomez L,. 2004. Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem 279: 47732-47739. (Pubitemid 39540921)
47. Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM,. 2002a. Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 49: 69-77.
48. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM,. 2002b. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 20: 241-251. (Pubitemid 34823752)
49. Wang G, Silva J, Krishnamurthy K, Tran E, Condie BG, Bieberich E,. 2005. Direct binding to ceramide activates protein kinase C zeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J Biol Chem 280: 26415-26424. (Pubitemid 41022238)
50. Xenaki D, Pierce A, Underhill-Day N, Whetton AD, Owen-Lynch PJ,. 2004. Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: A role for PKC betaII. Cell Signal 16: 145-156. (Pubitemid 37431164)
51. Yang E, Korsmeyer SJ,. 1996. Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88: 386-401. (Pubitemid 26240369)
52. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP,. 2004. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 279: 22118-22123. (Pubitemid 38679404)